Sonothrombolysis in Patients With STEMI
Launched by HARALD BECHER · Mar 21, 2017
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
This is a prospective, single center, single-arm study that examines pre-procedural sonothrombolysis as an adjuvant to contemporary therapy in patients with ST-segment elevation myocardial infarction receiving PPCI.This study is to examine what effect adding emergent diagnostic ultrasound (DUS) guided high mechanical index (HMI) impulses (sonothrombolysis), applied both before and after primary percutaneous coronary intervention (PPCI) during an intravenous commercially available microbubble infusion (Definity), have on spontaneous reperfusion (i.e. pre PCI coronary artery patency rates), m...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patients presenting with STEMI within 6 hours of symptom onset and:
- • 1. Are expected to receive reperfusion therapy with primary PCI
- 2. Have a high-risk STEMI ECG defined as:
- • ≥2mm ST-segment elevation in 2 anterior or lateral leads; or
- • ≥2 mm ST-segment elevation in 2 inferior leads coupled with ST segment depression in 2 contiguous anterior leads for a total ST-segment deviation of ≥4mm
- • 3. Age ≥30 years.
- • 4. Adequate apical and/or parasternal images by echocardiography
- Exclusion Criteria:
- • 1. Isolated inferior STEMI without anterior ST-segment depression
- • 2. Previous coronary bypass surgery
- • 3. Cardiogenic shock
- • 4. Known or suspected hypersensitivity to ultrasound contrast agent used for the study
- • 5. Life expectancy of less than two months or terminally ill.
- • 6. Known bleeding diathesis or contraindication to glycoprotein 2b/3a inhibitors, anticoagulants, or aspirin
- • 7. Known large right to left intracardiac shunts.
About Harald Becher
Harald Becher is a distinguished clinical trial sponsor renowned for his commitment to advancing medical research and innovation. With extensive experience in the pharmaceutical and biotechnology sectors, he focuses on developing novel therapies that address unmet medical needs. Under his leadership, the organization emphasizes rigorous study design, ethical standards, and patient safety, fostering collaborations with academic institutions and industry partners. By leveraging cutting-edge technologies and a patient-centric approach, Harald Becher is dedicated to delivering transformative solutions that enhance healthcare outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Patients applied
Trial Officials
Harald Becher
Principal Investigator
University of Alberta
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials